Aadi Bioscience, Inc. (NASDAQ:AADI) Short Interest Down 14.7% in May

Aadi Bioscience, Inc. (NASDAQ:AADIGet Free Report) was the recipient of a large drop in short interest during the month of May. As of May 15th, there was short interest totalling 964,000 shares, a drop of 14.7% from the April 30th total of 1,130,000 shares. Based on an average trading volume of 331,000 shares, the short-interest ratio is presently 2.9 days. Currently, 5.5% of the company’s shares are short sold.

Insider Buying and Selling

In other Aadi Bioscience news, Chairman Neil Desai sold 17,772 shares of the company’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $2.31, for a total value of $41,053.32. Following the completion of the sale, the chairman now directly owns 1,393,771 shares in the company, valued at approximately $3,219,611.01. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In the last three months, insiders sold 72,736 shares of company stock valued at $149,678. Insiders own 37.30% of the company’s stock.

Institutional Trading of Aadi Bioscience

An institutional investor recently bought a new position in Aadi Bioscience stock. Marquette Asset Management LLC purchased a new stake in Aadi Bioscience, Inc. (NASDAQ:AADIFree Report) during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 57,807 shares of the company’s stock, valued at approximately $135,000. Marquette Asset Management LLC owned 0.24% of Aadi Bioscience as of its most recent SEC filing. Institutional investors and hedge funds own 52.08% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “neutral” rating on shares of Aadi Bioscience in a research report on Tuesday, May 14th.

View Our Latest Stock Report on AADI

Aadi Bioscience Trading Up 3.7 %

Shares of NASDAQ AADI opened at $1.80 on Friday. Aadi Bioscience has a twelve month low of $1.55 and a twelve month high of $8.49. The stock has a fifty day simple moving average of $1.96 and a 200-day simple moving average of $2.40. The stock has a market capitalization of $44.19 million, a PE ratio of -0.71 and a beta of 0.64.

Aadi Bioscience (NASDAQ:AADIGet Free Report) last released its earnings results on Wednesday, May 8th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.02). The company had revenue of $5.35 million during the quarter, compared to analysts’ expectations of $6.41 million. Aadi Bioscience had a negative net margin of 288.72% and a negative return on equity of 61.83%. On average, equities analysts predict that Aadi Bioscience will post -2.54 earnings per share for the current year.

Aadi Bioscience Company Profile

(Get Free Report)

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.

Read More

Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.